Advertisement

Topics

Cellectis Reports 4th Quarter and Full Year 2016 Financial Results

16:30 EST 6 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
FDA approval to conduct Phase I clinical trials for UCART123 in AML & BPDCN patients UCART191 Phase I clinical trials ongoing in ALL patients; partial data presented at the NIH’s RAC’s meeting...

Other Sources for this Article

Media:
Jennifer Moore, VP Communications
+1 917-580-1088
media@cellectis.com
or
Caitlin Kasunich
KCSA Strategic Communications
+1 212.896.1241
ckasunich@kcsa.com
or
Investor relations:
Simon Harnest, VP Corporate Strategy and Finance
+1 646-385-9008
simon.harnest@cellectis.com

NEXT ARTICLE

More From BioPortfolio on "Cellectis Reports 4th Quarter and Full Year 2016 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement